MarketInOut Stock Screener Log In | Sign Up
 

PTC Therapeutics Inc

NASDAQ • Healthcare • Biotechnology • Quote as of 05/04/2026 16:00
PTC Therapeutics Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization5,401.7 mln
Float73.00 mln
Earnings Date05/07/2026

EPS

8.58
Strong

P / E

7.63
Undervalued

Piotroski F-Score

7 / 9
Strong

Beneish M-Score

-1.54
Likely manipulated

1-Year Forecast

88.07
Strong upside

Relative Strength

13 / 100
Significantly lagging

Business Description

PTC Therapeutics is a US-based drug development company focused on creating treatments for rare and serious conditions that affect both children and adults around the world. The company sells several approved medicines targeting diseases such as Duchenne muscular dystrophy, spinal muscular atrophy, and certain nervous system disorders, while also advancing a pipeline of new treatments for conditions like Huntington's disease and Friedreich's ataxia. PTC works alongside a number of notable partners, including Roche and Novartis, to develop and bring these therapies to patients. Founded in 1998 and headquartered in Warren, New Jersey, the company distributes its products through third-party partners across multiple markets.

Key Fundamentals

EPS8.58
P/E7.63
RPS20.10
ROIC85.44
ROA27.23
Interest Cover5.63
EBITDA, mln888
EV / EBITDA7.40
EV / EBIT7.73
Revenue, mln1,731
EV / Revenue3.79

Financial Strength

Altman Z-Score1.77
Piotroski F-Score 7 / 9
Beneish M-Score-1.54
1-Year Target Price88.07
Short Ratio8.64
Short % of Float14.01

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week -5.39% 12 / 100   
1 Month -3.36% 15 / 100   
2 Months -14.09% 24 / 100   
6 Months -3.85% 36 / 100   
1 Year 32.25% 72 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Contact Us